Cabazitaxel (jevtana): a novel agent for metastatic castration-resistant prostate cancer.

Article Details

Citation Copy to clipboard

Nightingale G, Ryu J

Cabazitaxel (jevtana): a novel agent for metastatic castration-resistant prostate cancer.

P T. 2012 Aug;37(8):440-8.

PubMed ID

23091336 [ View in PubMed

]

Abstract

OBJECTIVE: This article presents current clinical evidence supporting the use of cabazitaxel (Jevtana) in men with metastatic castration-resistant prostate cancer (mCRPC). DATA SOURCES: We conducted a literature search using abstracts from MEDLINE and PubMed (from January 1966 to December 2011) and the American Society of Clinical Oncology (from January 2000 to December 2011). The search included clinical studies and abstracts in the English language that described the pharmacology, pharmacokinetics, clinical activity, and safety of cabazitaxel in mCRPC. RESULTS: Cabazitaxel, a semisynthetic microtubule inhibitor that induces cell death by microtubule stabilization, was approved in combination with prednisone for the treatment of mCRPC in patients who had been treated with a docetaxel-(Taxotere)-containing regimen. The approval of this taxane derivative was based primarily on the results of a randomized, open-label trial in patients with mCRPC who were treated with either cabazitaxel 25 mg/m(2) or mitoxantrone (Novantrone) 12 mg/m(2) intravenously every 3 weeks, both in combination with prednisone 10 mg/day. The median survival period was 15.1 months with cabazitaxel and 12.7 months with mitoxantrone. Neither group experienced complete responses. Cabazitaxel has also shown activity in breast cancer and other malignancies. In clinical trials, common grade 3 or grade 4 adverse reactions were myelosuppression, febrile neutropenia, diarrhea, fatigue, and asthenia. Other adverse effects included abdominal pain, back pain, arthralgia, and peripheral neuropathy. CONCLUSION: Cabazitaxel appeared to be an effective second-line agent in patients with mCRPC refractory to a docetaxel-containing regimen. Studies comparing cabazitaxel with existing first-line regimens for mCRPC are under way. Until the results of these head-to-head trials are published, it remains uncertain whether cabazitaxel is more effective or more tolerable than the currently available first-line regimens.

DrugBank Data that Cites this Article

Drugs

Cabazitaxel

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Cabazitaxel	Tubulin beta-1 chain	Protein	Humans	Yes	Inhibitor	Details

Drug Interactions

Drugs	Interaction
Integrate drug-drug interactions in your software
Cabazitaxel Methimazole	The metabolism of Cabazitaxel can be decreased when combined with Methimazole.
Cabazitaxel Ritonavir	The metabolism of Cabazitaxel can be decreased when combined with Ritonavir.
Cabazitaxel Ketoconazole	The metabolism of Cabazitaxel can be decreased when combined with Ketoconazole.
Cabazitaxel Nefazodone	The metabolism of Cabazitaxel can be decreased when combined with Nefazodone.
Cabazitaxel Itraconazole	The metabolism of Cabazitaxel can be decreased when combined with Itraconazole.